hydroxychloroquine has been researched along with Raynaud Disease in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Raynaud Disease: An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For inflammatory arthritis, 79% of experts agreed (first- through fourth-line treatments were MTX, low-dose glucocorticoids, hydroxychloroquine, and rituximab or tocilizumab, respectively)." | 3.88 | Treatment Algorithms for Systemic Sclerosis According to Experts. ( Fernández-Codina, A; Pope, JE; Walker, KM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ward, JM | 1 |
| Hess, JN | 1 |
| Davis, LS | 1 |
| Bellan, M | 1 |
| Parisi, S | 1 |
| Stobbione, P | 1 |
| Pedrinelli, AR | 1 |
| Rizzi, E | 1 |
| Casciaro, GF | 1 |
| Vassia, V | 1 |
| Landi, R | 1 |
| Cittone, MG | 1 |
| Rigamonti, C | 1 |
| Patrucco, F | 1 |
| Ditto, MC | 1 |
| Finucci, A | 1 |
| Realmuto, C | 1 |
| Todoerti, M | 1 |
| Parodi, M | 1 |
| Rossi, P | 1 |
| Pirisi, M | 1 |
| Fusaro, E | 1 |
| Sainaghi, PP | 1 |
| Demarchi, J | 1 |
| Papasidero, S | 1 |
| Medina, MA | 1 |
| Klajn, D | 1 |
| Chaparro Del Moral, R | 1 |
| Rillo, O | 1 |
| Martiré, V | 1 |
| Crespo, G | 1 |
| Secco, A | 1 |
| Catalan Pellet, A | 1 |
| Amitrano, C | 1 |
| Crow, C | 1 |
| Asnal, C | 1 |
| Pucci, P | 1 |
| Caeiro, F | 1 |
| Benzanquen, N | 1 |
| Pirola, JP | 1 |
| Mayer, M | 1 |
| Zazzetti, F | 1 |
| Velez, S | 1 |
| Barreira, J | 1 |
| Tamborenea, N | 1 |
| Santiago, L | 1 |
| Raiti, L | 1 |
| Fernández-Codina, A | 1 |
| Walker, KM | 1 |
| Pope, JE | 1 |
| Nassarmadji, K | 1 |
| Marie, I | 1 |
| Calistru, AM | 1 |
| Lisboa, C | 1 |
| Cruz, MJ | 1 |
| Delgado, L | 1 |
| Poças, L | 1 |
| Azevedo, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis[NCT04986605] | Phase 2 | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| Pragmatic Clinical Trials in Scleroderma[NCT03610217] | 400 participants (Anticipated) | Interventional | 2018-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for hydroxychloroquine and Raynaud Disease
| Article | Year |
|---|---|
Targetoid-like Lesions in the Setting of Systemic Lupus Erythematosus: A Case of Rowell Syndrome.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Diagnosis, Differential; Erythema Multiforme; | 2020 |
Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Cohort Studies; COVID-19; Female; Humans; Hydroxychlo | 2020 |
Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Topics: Adult; Antirheumatic Agents; Fatigue; Female; Humans; Hydroxychloroquine; Hypergammaglobulinemia; In | 2017 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
[Abnormal nails].
Topics: Arthritis; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Middle Aged; Mixed Connectiv | 2018 |
Hypocomplementemic urticarial vasculitis in mixed connective tissue disease.
Topics: Complement C3c; Complement C4; Female; Humans; Hydroxychloroquine; Middle Aged; Mixed Connective Tis | 2010 |